Trials / Unknown
UnknownNCT01208545
Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- NeuroMetrix, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study hypothesis is that changes in serially obtained nerve conduction study data obtained every 3-4 weeks in cancer patients receiving chemotherapy can be used to predict the development of a clinically significant / disabling drug induced neuropathy six and twelve months following the start of treatment. Patients with breast cancer, colon cancer, gastroesophageal cancer, and non-Hodgkins lymphoma will be enrolled. Six lower extremity nerves--three in each leg--will be electrically stimulated and their responses recorded at three to four week intervals coinciding with patient's scheduled chemotherapy.
Conditions
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2010-07-01
- First posted
- 2010-09-24
- Last updated
- 2010-09-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01208545. Inclusion in this directory is not an endorsement.